These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 30614665)

  • 21. A comparison of gonadotropin-releasing hormone (GnRH) antagonist and GnRH agonist flare protocols for poor responders undergoing in vitro fertilization.
    Berin I; Stein DE; Keltz MD
    Fertil Steril; 2010 Feb; 93(2):360-3. PubMed ID: 19131055
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol.
    Hohmann FP; Macklon NS; Fauser BC
    J Clin Endocrinol Metab; 2003 Jan; 88(1):166-73. PubMed ID: 12519847
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stimulation of the young poor responder: comparison of the luteal estradiol/gonadotropin-releasing hormone antagonist priming protocol versus oral contraceptive microdose leuprolide.
    Shastri SM; Barbieri E; Kligman I; Schoyer KD; Davis OK; Rosenwaks Z
    Fertil Steril; 2011 Feb; 95(2):592-5. PubMed ID: 21074154
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Follicular synchronization using transdermal estradiol patch and GnRH antagonists in the luteal phase; does it increase oocyte yield in poor responders to gonadotropin stimulation for in vitro fertilization (IVF)? A comparative study with microdose flare-up protocol.
    Ata B; Zeng X; Son WY; Holzer H; Tan SL
    Gynecol Endocrinol; 2011 Nov; 27(11):876-9. PubMed ID: 21495800
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transdermal testosterone pretreatment in poor responders undergoing ICSI: a randomized clinical trial.
    Bosdou JK; Venetis CA; Dafopoulos K; Zepiridis L; Chatzimeletiou K; Anifandis G; Mitsoli A; Makedos A; Messinis IE; Tarlatzis BC; Kolibianakis EM
    Hum Reprod; 2016 May; 31(5):977-85. PubMed ID: 26956551
    [TBL] [Abstract][Full Text] [Related]  

  • 26. GnRH antagonist versus long GnRH agonist protocol in poor IVF responders: a randomized clinical trial.
    Prapas Y; Petousis S; Dagklis T; Panagiotidis Y; Papatheodorou A; Assunta I; Prapas N
    Eur J Obstet Gynecol Reprod Biol; 2013 Jan; 166(1):43-6. PubMed ID: 23020996
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of a gonadotropin-releasing hormone (GnRH) antagonist and GnRH agonist flare-up regimen in poor responders undergoing ovarian stimulation.
    Malmusi S; La Marca A; Giulini S; Xella S; Tagliasacchi D; Marsella T; Volpe A
    Fertil Steril; 2005 Aug; 84(2):402-6. PubMed ID: 16084881
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of different stimulation protocols efficacy in poor responders undergoing IVF: a retrospective study.
    Madani T; Ashrafi M; Yeganeh LM
    Gynecol Endocrinol; 2012 Feb; 28(2):102-5. PubMed ID: 22263965
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparisons of GnRH antagonist versus GnRH agonist protocol in poor ovarian responders undergoing IVF.
    Pu D; Wu J; Liu J
    Hum Reprod; 2011 Oct; 26(10):2742-9. PubMed ID: 21778283
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Luteal phase estradiol versus luteal phase estradiol and antagonist protocol for controlled ovarian stimulation before in vitro fertilization in poor responders.
    Elassar A; Mann JS; Engmann L; Nulsen J; Benadiva C
    Fertil Steril; 2011 Jan; 95(1):324-6. PubMed ID: 20797708
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The addition of gonadotrophin releasing hormone agonist to routine luteal phase support in intracytoplasmic sperm injection and embryo transfer cycles: a randomized clinical trial.
    Yıldız GA; Şükür YE; Ateş C; Aytaç R
    Eur J Obstet Gynecol Reprod Biol; 2014 Nov; 182():66-70. PubMed ID: 25238659
    [TBL] [Abstract][Full Text] [Related]  

  • 32. GnRH antagonist versus follicular-phase single-dose GnRH agonist protocol in patients of normal ovarian responses during controlled ovarian stimulation.
    Geng Y; Xun Y; Hu S; Lai Q; Jin L
    Gynecol Endocrinol; 2019 Apr; 35(4):309-313. PubMed ID: 30430883
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Estradiol Pretreatment in an Ultrashort GnRH Combined with a GnRH Antagonist Protocol in A Cohort of Poor Responders Undergoing IVF/ICSI: A Case-control Study.
    Siristatidis C; Salamalekis G; Vogiatzi P; Vrantza T; Matsota P; Pergialiotis V; Papantoniou N
    In Vivo; 2016 11-12; 30(6):945-950. PubMed ID: 27815485
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Minimal stimulation protocol using letrozole versus microdose flare up GnRH agonist protocol in women with poor ovarian response undergoing ICSI.
    Mohsen IA; El Din RE
    Gynecol Endocrinol; 2013 Feb; 29(2):105-8. PubMed ID: 23134528
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The comparision of effect of microdose GnRH-a flare-up, GnRH antagonist/aromatase inhibitor letrozole and GnRH antagonist/clomiphene citrate protocols on IVF outcomes in poor responder patients.
    Ozcan Cenksoy P; Ficicioglu C; Kizilkale O; Suhha Bostanci M; Bakacak M; Yesiladali M; Kaspar C
    Gynecol Endocrinol; 2014 Jul; 30(7):485-9. PubMed ID: 24592985
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study.
    Engmann L; DiLuigi A; Schmidt D; Nulsen J; Maier D; Benadiva C
    Fertil Steril; 2008 Jan; 89(1):84-91. PubMed ID: 17462639
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Beneficial effect of luteal-phase GnRH agonist administration on embryo implantation after ICSI in both GnRH agonist- and antagonist-treated ovarian stimulation cycles.
    Tesarik J; Hazout A; Mendoza-Tesarik R; Mendoza N; Mendoza C
    Hum Reprod; 2006 Oct; 21(10):2572-9. PubMed ID: 16926261
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gonadotropin-releasing hormone (GnRH)-antagonist versus GnRH-agonist in ovarian stimulation of poor responders undergoing IVF.
    Fasouliotis SJ; Laufer N; Sabbagh-Ehrlich S; Lewin A; Hurwitz A; Simon A
    J Assist Reprod Genet; 2003 Nov; 20(11):455-60. PubMed ID: 14714824
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of transdermal testosterone in poor responders undergoing IVF: systematic review and meta-analysis.
    González-Comadran M; Durán M; Solà I; Fábregues F; Carreras R; Checa MA
    Reprod Biomed Online; 2012 Nov; 25(5):450-9. PubMed ID: 22999555
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Luteal phase characteristics following GnRH antagonist or agonist treatment - a comparative study.
    Friedler S; Gilboa S; Schachter M; Raziel A; Strassburger D; Ron El R
    Reprod Biomed Online; 2006 Jan; 12(1):27-32. PubMed ID: 16454930
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.